Atossa Genetics Inc. (ATOS) Short Interest Update
Atossa Genetics Inc. (NASDAQ:ATOS) saw a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 1,960,626 shares, a growth of 53.5% from the November 15th total of 1,277,644 shares. Based on an average daily volume of 993,858 shares, the short-interest ratio is currently 2.0 days. Approximately 8.2% of the company’s stock are short sold.
An institutional investor recently bought a new position in Atossa Genetics stock. Sabby Management LLC acquired a new stake in shares of Atossa Genetics Inc. (NASDAQ:ATOS) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 291,046 shares of the company’s stock, valued at approximately $150,000. Sabby Management LLC owned 2.49% of Atossa Genetics as of its most recent SEC filing. Institutional investors and hedge funds own 3.61% of the company’s stock.
Shares of Atossa Genetics (ATOS) opened at $0.33 on Friday. Atossa Genetics has a 12 month low of $0.28 and a 12 month high of $1.85.
ILLEGAL ACTIVITY NOTICE: “Atossa Genetics Inc. (ATOS) Short Interest Update” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/15/atossa-genetics-inc-atos-short-interest-update.html.
Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.